
65 cardiovascular sites. 2 to 3 days to feasibility.
How AcceleTrial compressed feasibility timelines for a global ACS trial with an innovative LDL-lowering drug, exceeding the sponsor's site targets and turnaround expectations.
The Challenge
60 cardiovascular sites for LDL-lowering drug trial
Identifying sites with cardiovascular expertise, patient access, and operational readiness for an ACS study.
Acquiring CDAs and FQs under compression
Communicating with a large number of sites and executing study documents within a compressed schedule.
Timely activation to accelerate trial timeline
Activating sites quickly to prevent downstream delays in the overall study schedule.
The Solution
Using AcceleTrial, LINEA identified 65 sites with cardiovascular trial expertise. Feasibility and CDAs were completed in 2 to 3 days, exceeding the sponsor's expectations. All documents were collected at a 50% faster rate. Sites were evaluated against trial history, COVID-readiness, debarment, and clinical experience.
Site Criteria
Outcomes
65 Sites Identified
Exceeded sponsor target of 60, with full qualification against cardiovascular protocol criteria.
2-3 Day Turnaround
Feasibility and CDAs completed in 2 to 3 days, exceeding the sponsor's stated expectations.
46 Sites Selected
46 LINEA sites selected for inclusion in the ACS study.